Loading company
Bull, base and bear scenarios, opening on what this business has actually done — its realised growth rates and its own P/E range, not round numbers we chose.
Projections are part of Pro
Set the growth, margin and multiple yourself and watch the price land where your assumptions put it — for Protagonist Therapeutics, Inc. and every other company we cover.
Try it first on NVDA, AAPL, META, NKE or CAKE, where it is open to everyone.
$130.83-2.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 6, 2026
Protagonist licenses medicines for psoriasis and a rare blood disorder to drug companies, which pay milestone fees and royalties, while developing treatments for obesity.